Lilly(Eli) & Co

NYSE:LLY  
195.52
+1.63 (+0.84%)
4:00:00 PM EDT: $195.31 -0.21 (-0.11%)
Earnings Announcements

Lilly Announces Agreement To Acquire Prevail Therapeutics

Published: 12/15/2020 11:46 GMT
Lilly(Eli) & Co (LLY) - Lilly Announces Agreement to Acquire Prevail Therapeutics.
Eli Lilly - Lilly to Acquire Prevail for $22.50 per Share in Cash Payable at Closing Plus One Non-tradable Cvr Worth Up to $4 per Share in Cash.
Eli Lilly - Deal for Total Consideration of Up to $26.50 per Share in Cash.
Eli Lilly - Cvr is Payable Upon First Regulatory Approval of a Product From Prevail's Pipeline.
Eli Lilly - Transaction is Not Subject to Any Financing Condition.
Eli Lilly - Upon Closing, Impact of Deal Will Be Reflected in Lilly's 2021 GAAP Financial Results.
Revenue is expected to be $6.66 Billion
Adjusted EPS is expected to be $1.94

Next Quarter Revenue Guidance is expected to be $6.62 Billion
Next Quarter EPS Guidance is expected to be $1.91

More details on our Analysts Page.